智通财经APP获悉，据港交所6月13日披露，轩竹生物科技股份有限公司(简称：轩竹生物)向港交所主板递交 上市申请，中金公司为独家保荐人。该公司曾于2024年11月25日递表港交所。 业绩方面，于2023年度、2024年度、2024年以及2025年截至3月31日止三个月，轩竹生物实现收入分别为2.9 万元、3009.4万元、651.4万元、255.9万人民币；同期，年/期内亏损及全面亏损总额分别为约3.01亿元、约 5.56亿元、5173.4万元、6546.1万元人民币。 | | 截至12月31日止年度 | | 截至3月31日止三個月 | | | --- | --- | --- | --- | --- | | | 2023年 | 2024年 | 2024年 | 2025年 | | | (人民幣千元)(人民幣千元) | | (人民幣千元)(人民幣千元) | | | | | | (未經審計) | | | 收入 | 29 | 30,094 | 6.514 | 2.559 | | 銷售成本 | (9) | (13,602) | (3,202) | (795) | | 其他收入及收益 | 40,800 | 15.349 ...

Group 1 - Xiaofang Pharmaceutical announced a collaboration with Shanghai Skin Disease Hospital to develop a new traditional Chinese medicine for hair loss, Compound Cèbǎi Tincture, which is expected to be the first TCM formulation for hair loss in China [1] - Guizhou Sanli plans to invest 150 million RMB in a patent transfer and technical cooperation contract with Guangdong Pharmaceutical University for the development of a new TCM drug [1] - The technical cooperation will involve a total development cost of 100 million RMB for the research and development of SL&GDPU-001, a new TCM drug [2] Group 2 - Jichuan Pharmaceutical's actual controller, Cao Longxiang, transferred part of his equity in Jichuan Holdings to his son, Cao Fei, which is an internal family equity adjustment and will not affect the company's independence [2] - Junshi Biosciences received acceptance for the clinical trial application of JT118 injection, a vaccine aimed at preventing monkeypox virus infection, marking a significant step as no such vaccine has been approved in China [3] - Palin Bio announced that its controlling shareholder, Shengbang Yinghao, intends to transfer 21.03% of its shares to China National Pharmaceutical Group, which will result in a change of control [3] Group 3 - East China Pharmaceutical's subsidiary received FDA approval for the clinical trial of HDM1010 tablets, aimed at treating type 2 diabetes, enhancing the company's competitiveness in the endocrine field [4]

Group 1 - Guizhou Sanli plans to sign a technology transfer and development contract with Guangdong Pharmaceutical University, with a total contract amount of RMB 150 million [1] - The technology contract involves the transfer of a patent for the use of Jinlv Banfenghe in the preparation of drugs for liver injury prevention and treatment, along with other related patents [1][2] - The patent transfer was successfully completed for RMB 50 million, with the transaction taking place on June 11, 2025 [1] Group 2 - The contract stipulates an overall transfer fee of RMB 50 million for the patent rights, with an initial payment of RMB 5 million due within 10 working days after signing [2] - The total development cost for the technical cooperation is RMB 100 million, with payments to be made in installments based on contract terms [2]